Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBPP) Research & Development (2016 - 2024)

Historic Research & Development for Regen BioPharma (RGBPP) over the last 12 years, with Q3 2024 value amounting to $33524.0.

  • Regen BioPharma's Research & Development fell 513.06% to $33524.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $153685.0, marking a year-over-year decrease of 2760.85%. This contributed to the annual value of $11725.0 for FY2025, which is 9237.08% down from last year.
  • Per Regen BioPharma's latest filing, its Research & Development stood at $33524.0 for Q3 2024, which was down 513.06% from $32500.0 recorded in Q2 2024.
  • Regen BioPharma's Research & Development's 5-year high stood at $95513.0 during Q4 2022, with a 5-year trough of $12.0 in Q2 2020.
  • For the 5-year period, Regen BioPharma's Research & Development averaged around $29820.6, with its median value being $32500.0 (2024).
  • As far as peak fluctuations go, Regen BioPharma's Research & Development crashed by 9992.17% in 2020, and later soared by 11868333.33% in 2021.
  • Over the past 5 years, Regen BioPharma's Research & Development (Quarter) stood at $1127.0 in 2020, then skyrocketed by 3042.68% to $35418.0 in 2021, then surged by 169.67% to $95513.0 in 2022, then tumbled by 50.24% to $47528.0 in 2023, then fell by 29.46% to $33524.0 in 2024.
  • Its last three reported values are $33524.0 in Q3 2024, $32500.0 for Q2 2024, and $40133.0 during Q1 2024.